المؤلفون: Pedersini R; Medical Oncology Department, ASST-Spedali Civili of Brescia, Brescia, Italy; SSVD Breast Unit, ASST-Spedali Civili of Brescia, Brescia, Italy., Buffoni M; Medical Oncology Department, ASST-Spedali Civili of Brescia, Brescia, Italy. Electronic address: martinabuffoni97@gmail.com., Petrelli F; Medical Oncology, Caravaggio Hospital, Treviglio, Italy., Ghidini A; Medical Oncology, Casa di Cura Igea, Milano, Italy., di Mauro P; Medical Oncology Department, ASST-Spedali Civili of Brescia, Brescia, Italy., Amoroso V; Medical Oncology Department, ASST-Spedali Civili of Brescia, Brescia, Italy., Parati MC; Medical Oncology, Caravaggio Hospital, Treviglio, Italy., Laini L; Medical Oncology Department, ASST-Spedali Civili of Brescia, Brescia, Italy., Cosentini D; Medical Oncology Department, ASST-Spedali Civili of Brescia, Brescia, Italy., Schivardi G; Medical Oncology Department, ASST-Spedali Civili of Brescia, Brescia, Italy., Ippolito G; Medical Oncology Department, ASST-Spedali Civili of Brescia, Brescia, Italy., Berruti A; Medical Oncology Department, ASST-Spedali Civili of Brescia, Brescia, Italy., Laganà M; Medical Oncology Department, ASST-Spedali Civili of Brescia, Brescia, Italy.

المصدر: Clinical breast cancer [Clin Breast Cancer] 2024 Jul; Vol. 24 (5), pp. 411-420. Date of Electronic Publication: 2024 Apr 08.

نوع المنشور: Journal Article; Review

بيانات الدورية: Publisher: Elsevier Country of Publication: United States NLM ID: 100898731 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1938-0666 (Electronic) Linking ISSN: 15268209 NLM ISO Abbreviation: Clin Breast Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Breast Neoplasms*/drug therapy , Breast Neoplasms*/pathology , Immunoconjugates*/adverse effects , Immunoconjugates*/therapeutic use , Gastrointestinal Diseases*/chemically induced , Ado-Trastuzumab Emtansine*/therapeutic use , Ado-Trastuzumab Emtansine*/adverse effects , Antibodies, Monoclonal, Humanized*/adverse effects , Antibodies, Monoclonal, Humanized*/therapeutic use, Humans ; Female ; Trastuzumab/adverse effects ; Trastuzumab/therapeutic use ; Camptothecin/analogs & derivatives ; Camptothecin/therapeutic use ; Camptothecin/adverse effects ; Nausea/chemically induced ; Neoplasm Metastasis ; Antineoplastic Agents, Immunological/adverse effects ; Antineoplastic Agents, Immunological/therapeutic use

المؤلفون: Kim HJ; Department of Digital Health, Samsung Advanced Institute for Health Science and Technology, Sungkyunkwan University, Seoul, Republic of Korea.; Center of Research Resource Standardization, Research Institution for Future Medicine, Samsung Medical Center, Seoul, Republic of Korea., Yoon JH; Institute of Health Policy and Management, Medical Research Center, Seoul National University, Seoul, Republic of Korea.; Medical Big Data Research Center, Medical Research Center, Seoul National University, Seoul, Republic of Korea., Park YH; Samsung Advanced Institute for Health Science and Technology (SAIHST), Sungkyunkwan University, Seoul, Republic of Korea. yhparkhmo@skku.edu.; Division of Hematology-Oncology, Department of Medicine, Breast Cancer Center, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro Gangnam-gu, Seoul, 06351, Republic of Korea. yhparkhmo@skku.edu.

المصدر: Scientific reports [Sci Rep] 2024 Aug 23; Vol. 14 (1), pp. 19587. Date of Electronic Publication: 2024 Aug 23.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE

مواضيع طبية MeSH: Ado-Trastuzumab Emtansine*/adverse effects , Ado-Trastuzumab Emtansine*/therapeutic use , Adverse Drug Reaction Reporting Systems* , United States Food and Drug Administration* , Pharmacovigilance* , Breast Neoplasms*/drug therapy, Humans ; United States ; Female ; Middle Aged ; Databases, Factual ; Chemical and Drug Induced Liver Injury/etiology ; Chemical and Drug Induced Liver Injury/epidemiology ; Trastuzumab/adverse effects ; Adult ; Antineoplastic Agents, Immunological/adverse effects ; Aged ; Biliary Tract Diseases/chemically induced ; Liver Diseases/epidemiology

المؤلفون: Takano T; Department of Breast Medical Oncology, The Cancer Institute Hospital of JFCR, Tokyo, Japan., Masuda N; Department of Breast and Endocrine Surgery, Nagoya University Graduate School of Medicine, 65 Tsurumai-Cho, Showa-Ku, Nagoya, Aichi, 466-8550, Japan. nmasuda@alpha.ocn.ne.jp.; Department of Breast Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan. nmasuda@alpha.ocn.ne.jp., Ito M; Department of Breast Surgery, Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan., Inoue K; Division of Breast Oncology, Saitama Cancer Center, Saitama, Japan., Tanabe Y; Department of Medical Oncology, Toranomon Hospital, Tokyo, Japan., Kawaguchi K; Department of Breast Surgery, Kyoto University Hospital, Kyoto, Japan., Yasojima H; Department of Surgery, Breast Oncology, NHO Osaka National Hospital, Osaka, Japan., Bando H; Breast and Endocrine Surgery, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan., Nakamura R; Division of Breast Surgery, Chiba Cancer Center, Chiba, Japan., Yamanaka T; Department of Breast Surgery and Oncology, Kanagawa Cancer Center, Yokohama, Japan., Ishida K; Department of Surgery, Iwate Medical University, Morioka, Japan., Aruga T; Surgery (Breast), Tokyo Metropolitan Komagome Hospital, Tokyo, Japan., Yanagita Y; Department of Breast Oncology, Gunma Prefectural Cancer Center, Ota, Japan., Tokunaga E; Department of Breast Oncology, NHO Kyushu Cancer Center, Fukuoka, Japan., Aogi K; Department of Breast Oncology, NHO Shikoku Cancer Center, Matsuyama, Japan., Ohno S; Department of Breast Medical Oncology, The Cancer Institute Hospital of JFCR, Tokyo, Japan., Kasai H; Clinical Research, Innovation and Education Center, Tohoku University Hospital, Sendai, Japan., Kataoka TR; Department of Diagnostic Pathology, Iwate Medical University, Morioka, Japan., Morita S; Department of Biomedical Statistics and Bioinformatics, Kyoto University Graduate School of Medicine, Kyoto, Japan., Toi M; Tokyo Metropolitan Komagome Hospital, Tokyo, Japan.

المصدر: Breast cancer research and treatment [Breast Cancer Res Treat] 2024 Aug; Vol. 207 (1), pp. 33-48. Date of Electronic Publication: 2024 May 20.

نوع المنشور: Journal Article; Clinical Trial, Phase II; Randomized Controlled Trial

بيانات الدورية: Publisher: Kluwer Academic Country of Publication: Netherlands NLM ID: 8111104 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-7217 (Electronic) Linking ISSN: 01676806 NLM ISO Abbreviation: Breast Cancer Res Treat Subsets: MEDLINE

مواضيع طبية MeSH: Breast Neoplasms*/drug therapy , Breast Neoplasms*/pathology , Breast Neoplasms*/mortality , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/adverse effects , Neoadjuvant Therapy*/methods , Carboplatin*/administration & dosage , Trastuzumab*/administration & dosage , Docetaxel*/administration & dosage , Receptor, ErbB-2*/metabolism , Antibodies, Monoclonal, Humanized*/administration & dosage, Humans ; Female ; Middle Aged ; Adult ; Aged ; Ado-Trastuzumab Emtansine/administration & dosage ; Ado-Trastuzumab Emtansine/therapeutic use ; Prognosis ; Treatment Outcome

المؤلفون: Ma G; Institut für Chemie und Biochemie, Freie Universität Berlin, Takustr. 3, Berlin 14195, Germany., Braatz D; Institut für Chemie und Biochemie, Freie Universität Berlin, Takustr. 3, Berlin 14195, Germany., Tang P; Institut für Chemie und Biochemie, Freie Universität Berlin, Takustr. 3, Berlin 14195, Germany., Yang Y; Institut für Chemie und Biochemie, Freie Universität Berlin, Takustr. 3, Berlin 14195, Germany., Quaas E; Institut für Chemie und Biochemie, Freie Universität Berlin, Takustr. 3, Berlin 14195, Germany., Ludwig K; Institut für Chemie und Biochemie, Freie Universität Berlin, Takustr. 3, Berlin 14195, Germany., Ma N; Institut für Chemie und Biochemie, Freie Universität Berlin, Takustr. 3, Berlin 14195, Germany.; Institute of Active Polymers, Helmholtz-Zentrum HEREON, Teltow 14513, Germany., Sun H; Biomedical Polymers Laboratory, College of Chemistry, Chemical Engineering and Materials Science, and State Key Laboratory of Radiation Medicine and Protection, Soochow University, Suzhou 215123, PR China., Zhong Z; Biomedical Polymers Laboratory, College of Chemistry, Chemical Engineering and Materials Science, and State Key Laboratory of Radiation Medicine and Protection, Soochow University, Suzhou 215123, PR China., Haag R; Institut für Chemie und Biochemie, Freie Universität Berlin, Takustr. 3, Berlin 14195, Germany.

المصدر: Biomacromolecules [Biomacromolecules] 2024 Jul 08; Vol. 25 (7), pp. 4440-4448. Date of Electronic Publication: 2024 Jun 22.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: American Chemical Society Country of Publication: United States NLM ID: 100892849 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1526-4602 (Electronic) Linking ISSN: 15257797 NLM ISO Abbreviation: Biomacromolecules Subsets: MEDLINE

مواضيع طبية MeSH: Breast Neoplasms*/drug therapy , Breast Neoplasms*/pathology , Breast Neoplasms*/metabolism , Glycerol*/chemistry , Polymers*/chemistry , Trastuzumab*/pharmacology , Trastuzumab*/chemistry , Trastuzumab*/administration & dosage , Receptor, ErbB-2*/metabolism, Humans ; Female ; Cell Line, Tumor ; Drug Delivery Systems/methods ; Ado-Trastuzumab Emtansine/pharmacology

المؤلفون: Chun SJ; Department of Radiation Oncology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea; Department of Radiation Oncology, Dongguk University Ilsan Hospital, Dongguk University College of Medicine, Goyang, South Korea., Kim K; Department of Radiation Oncology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, South Korea. Electronic address: kyubokim.ro@gmail.com., Kim YB; Department of Radiation Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea., Paek SH; Department of Neurosurgery, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea., Lee KH; Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea., Song JH; Department of Radiation Oncology, Seoul St. Mary's Hospital, The Catholic University of Korea College of Medicine, Seoul, South Korea., Jang WI; Department of Radiation Oncology, Korea Institute of Radiological & Medical Sciences, Seoul, South Korea., Kim TH; Center for Proton Therapy, National Cancer Center, Goyang, South Korea., Salvestrini V; Breast Unit & Radiation Oncology Unit, Oncology Department, Azienda Ospedaliero Universitaria Careggi, Florence, Italy., Meattini I; Breast Unit & Radiation Oncology Unit, Oncology Department, Azienda Ospedaliero Universitaria Careggi, Florence, Italy; Department of Experimental and Clinical Biomedical Sciences 'M. Serio', University of Florence, Florence, Italy., Livi L; Breast Unit & Radiation Oncology Unit, Oncology Department, Azienda Ospedaliero Universitaria Careggi, Florence, Italy; Department of Experimental and Clinical Biomedical Sciences 'M. Serio', University of Florence, Florence, Italy., Shin KH; Department of Radiation Oncology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea. Electronic address: radiat@snu.ac.kr.

المصدر: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology [Radiother Oncol] 2024 Oct; Vol. 199, pp. 110461. Date of Electronic Publication: 2024 Jul 25.

نوع المنشور: Journal Article; Multicenter Study

بيانات الدورية: Publisher: Elsevier Scientific Publishers Country of Publication: Ireland NLM ID: 8407192 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0887 (Electronic) Linking ISSN: 01678140 NLM ISO Abbreviation: Radiother Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Breast Neoplasms*/pathology , Radiosurgery*/adverse effects , Brain Neoplasms*/secondary , Ado-Trastuzumab Emtansine*/therapeutic use , Ado-Trastuzumab Emtansine*/adverse effects , Necrosis*/etiology , Radiation Injuries*/etiology , Radiation Injuries*/pathology , Receptor, ErbB-2*/metabolism , Antineoplastic Agents, Immunological*/therapeutic use , Antineoplastic Agents, Immunological*/adverse effects, Humans ; Female ; Middle Aged ; Retrospective Studies ; Aged ; Adult ; Trastuzumab/therapeutic use ; Trastuzumab/adverse effects ; Combined Modality Therapy

المؤلفون: Paulissen JHJ; Department of Health Sciences, University Medical Center Groningen, Groningen, The Netherlands. j.h.j.paulissen@umcg.nl.; Asc Academics, Groningen, The Netherlands. j.h.j.paulissen@umcg.nl., Seddik AH; Daiichi Sankyo Europe GmbH, Munich, Germany., Dunton KJ; Daiichi Sankyo UK Ltd, Uxbridge, UK., Livings CJ; AstraZeneca Plc., Cambridge, UK., van Hulst M; Department of Health Sciences, University Medical Center Groningen, Groningen, The Netherlands.; Department of Clinical Pharmacy and Toxicology, Martini Hospital, Groningen, The Netherlands., Postma MJ; Department of Health Sciences, University Medical Center Groningen, Groningen, The Netherlands., de Jong LA; Department of Health Sciences, University Medical Center Groningen, Groningen, The Netherlands., Freriks RD; Asc Academics, Groningen, The Netherlands.; Department of Economics, Econometrics and Finance, Faculty of Economics & Business, University of Groningen, Groningen, The Netherlands.

المصدر: The European journal of health economics : HEPAC : health economics in prevention and care [Eur J Health Econ] 2024 Jun; Vol. 25 (4), pp. 689-699. Date of Electronic Publication: 2023 Jul 24.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Springer-Verlag Country of Publication: Germany NLM ID: 101134867 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1618-7601 (Electronic) Linking ISSN: 16187598 NLM ISO Abbreviation: Eur J Health Econ Subsets: MEDLINE

مواضيع طبية MeSH: Breast Neoplasms*/drug therapy , Breast Neoplasms*/pathology , Cost-Benefit Analysis* , Trastuzumab*/therapeutic use , Trastuzumab*/economics , Quality-Adjusted Life Years* , Receptor, ErbB-2*/metabolism , Camptothecin*/analogs & derivatives , Camptothecin*/therapeutic use , Camptothecin*/economics, Humans ; Finland ; Female ; Antineoplastic Agents, Immunological/therapeutic use ; Antineoplastic Agents, Immunological/economics ; Ado-Trastuzumab Emtansine/therapeutic use ; Ado-Trastuzumab Emtansine/economics ; Survival Analysis ; Middle Aged ; Adult ; Immunoconjugates

المؤلفون: Kınıkoğlu O; Department of Medical Oncology, Health Science University, Kartal Dr. Lütfi Kirdar City Hospital, Istanbul 34865, Turkey., Odabas H; Department of Medical Oncology, Health Science University, Kartal Dr. Lütfi Kirdar City Hospital, Istanbul 34865, Turkey., Altıntaş YE; Department of Medical Oncology, Health Science University, Kartal Dr. Lütfi Kirdar City Hospital, Istanbul 34865, Turkey., Yıldız A; Department of Medical Oncology, Istanbul University Oncology Institute, Istanbul 34093, Turkey., Çakan B; Department of Medical Oncology, Bağcılar Research and Training Hospital, Istanbul 34212, Turkey., Akdağ G; Department of Medical Oncology, Health Science University, Kartal Dr. Lütfi Kirdar City Hospital, Istanbul 34865, Turkey., Yıldırım S; Department of Medical Oncology, Health Science University, Kartal Dr. Lütfi Kirdar City Hospital, Istanbul 34865, Turkey., Bal H; Department of Medical Oncology, Health Science University, Kartal Dr. Lütfi Kirdar City Hospital, Istanbul 34865, Turkey., Kaya T; Department of Medical Oncology, Health Science University, Kartal Dr. Lütfi Kirdar City Hospital, Istanbul 34865, Turkey., Tünbekici S; Department of Medical Oncology, Ege University Faculty of Medicine, Izmir 35100, Turkey., Işık D; Department of Medical Oncology, Health Science University, Kartal Dr. Lütfi Kirdar City Hospital, Istanbul 34865, Turkey., Başoğlu T; Department of Medical Oncology, Health Science University, Kartal Dr. Lütfi Kirdar City Hospital, Istanbul 34865, Turkey., Yıldırım ME; Department of Medical Oncology, Health Science University, Kartal Dr. Lütfi Kirdar City Hospital, Istanbul 34865, Turkey., Turan N; Department of Medical Oncology, Health Science University, Kartal Dr. Lütfi Kirdar City Hospital, Istanbul 34865, Turkey.

المصدر: Medicina (Kaunas, Lithuania) [Medicina (Kaunas)] 2024 Jun 07; Vol. 60 (6). Date of Electronic Publication: 2024 Jun 07.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 9425208 Publication Model: Electronic Cited Medium: Internet ISSN: 1648-9144 (Electronic) Linking ISSN: 1010660X NLM ISO Abbreviation: Medicina (Kaunas) Subsets: MEDLINE

مواضيع طبية MeSH: Breast Neoplasms*/drug therapy , Breast Neoplasms*/mortality , Receptor, ErbB-2*/analysis , Ado-Trastuzumab Emtansine*/therapeutic use , Progression-Free Survival*, Humans ; Female ; Middle Aged ; Aged ; Adult ; Retrospective Studies ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/pharmacology ; Antineoplastic Agents, Immunological/therapeutic use ; Antineoplastic Agents, Immunological/pharmacology ; Neoplasm Metastasis ; Aged, 80 and over ; Trastuzumab/therapeutic use ; Receptors, Estrogen/analysis ; Receptors, Estrogen/metabolism

المؤلفون: Gedik ME; Department of Biochemistry and Molecular Biology, Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina., Saatci O; Department of Biochemistry and Molecular Biology, Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina.; Department of Drug Discovery and Biomedical Sciences, University of South Carolina, Columbia, South Carolina., Oberholtzer N; Department of Surgery, Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina., Uner M; Department of Pathology, Faculty of Medicine, Hacettepe University, Ankara, Turkey., Akbulut Caliskan O; Department of Molecular Biology and Genetics, Bilkent University, Ankara, Turkey., Cetin M; Department of Biochemistry and Molecular Biology, Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina.; Department of Drug Discovery and Biomedical Sciences, University of South Carolina, Columbia, South Carolina., Aras M; Department of Drug Discovery and Biomedical Sciences, University of South Carolina, Columbia, South Carolina., Ibis K; Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Gazi University, Ankara, Turkey., Caliskan B; Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Gazi University, Ankara, Turkey., Banoglu E; Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Gazi University, Ankara, Turkey., Wiemann S; Division of Molecular Genome Analysis, German Cancer Research Center (DKFZ), INF580, Heidelberg, Germany., Üner A; Department of Pathology, Faculty of Medicine, Hacettepe University, Ankara, Turkey., Aksoy S; Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, Turkey., Mehrotra S; Department of Surgery, Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina., Sahin O; Department of Biochemistry and Molecular Biology, Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina.; Department of Drug Discovery and Biomedical Sciences, University of South Carolina, Columbia, South Carolina.

المصدر: Cancer research [Cancer Res] 2024 May 02; Vol. 84 (9), pp. 1475-1490.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural

بيانات الدورية: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 2984705R Publication Model: Print Cited Medium: Internet ISSN: 1538-7445 (Electronic) Linking ISSN: 00085472 NLM ISO Abbreviation: Cancer Res Subsets: MEDLINE

مواضيع طبية MeSH: Breast Neoplasms*/immunology , Breast Neoplasms*/drug therapy , Breast Neoplasms*/pathology , Breast Neoplasms*/metabolism , Breast Neoplasms*/genetics , Immunogenic Cell Death*/drug effects , Receptor, ErbB-2*/metabolism , Ado-Trastuzumab Emtansine*/pharmacology , Ado-Trastuzumab Emtansine*/therapeutic use , Microtubule-Associated Proteins*/metabolism , Microtubule-Associated Proteins*/genetics , Microtubule-Associated Proteins*/immunology, Humans ; Female ; Animals ; Mice ; Xenograft Model Antitumor Assays ; Cell Line, Tumor ; Antineoplastic Agents, Immunological/pharmacology ; Antineoplastic Agents, Immunological/therapeutic use ; Drug Resistance, Neoplasm/immunology ; Drug Resistance, Neoplasm/drug effects ; Antigens, Neoplasm/immunology ; Antigens, Neoplasm/genetics ; Trastuzumab/pharmacology ; Trastuzumab/therapeutic use ; CD8-Positive T-Lymphocytes/immunology

المؤلفون: Jacobs SA; NSABP Foundation, Pittsburgh, PA, USA. jacobssa1945@gmail.com., Wang Y; NSABP Foundation, Pittsburgh, PA, USA., Abraham J; NSABP Foundation, Pittsburgh, PA, USA.; Cleveland Clinic, Weston/Taussig Cancer Institute, Cleveland, OH, USA., Feng H; NSABP Foundation, Pittsburgh, PA, USA., Montero AJ; NSABP Foundation, Pittsburgh, PA, USA.; Cleveland Clinic, Weston/Taussig Cancer Institute, Cleveland, OH, USA.; University Hospitals/Seidman Cancer Center, Case Western Reserve University, Cleveland, OH, USA., Lipchik C; NSABP Foundation, Pittsburgh, PA, USA., Finnigan M; NSABP Foundation, Pittsburgh, PA, USA., Jankowitz RC; NSABP Foundation, Pittsburgh, PA, USA.; University of Pittsburgh, Pittsburgh, PA, USA.; University of Pennsylvania Perelman School of Medicine, State College, PA, USA., Salkeni MA; NSABP Foundation, Pittsburgh, PA, USA.; National Institutes of Health, Washington, DC, USA.; Virginia Cancer Specialists, Fairfax, VA, USA., Maley SK; NSABP Foundation, Pittsburgh, PA, USA., Puhalla SL; NSABP Foundation, Pittsburgh, PA, USA.; UPMC Hillman Cancer Center, Pittsburgh, PA, USA.; University of Pittsburgh School of Medicine, Pittsburgh, PA, USA., Piette F; International Drug Development Institute, Louvain-la-Neuve, Belgium., Quinn K; Guardant Health, Redwood City, CA, USA., Chang K; Guardant Health, Redwood City, CA, USA., Nagy RJ; Guardant Health, Redwood City, CA, USA., Allegra CJ; NSABP Foundation, Pittsburgh, PA, USA.; University of Florida Health, Gainesville, FL, USA., Vehec K; NSABP Foundation, Pittsburgh, PA, USA., Wolmark N; NSABP Foundation, Pittsburgh, PA, USA.; UPMC Hillman Cancer Center, Pittsburgh, PA, USA., Lucas PC; NSABP Foundation, Pittsburgh, PA, USA.; UPMC Hillman Cancer Center, Pittsburgh, PA, USA.; University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA., Srinivasan A; NSABP Foundation, Pittsburgh, PA, USA.; Autism Impact Fund, Pittsburgh, PA, USA., Pogue-Geile KL; NSABP Foundation, Pittsburgh, PA, USA.

المصدر: Breast cancer research : BCR [Breast Cancer Res] 2024 Apr 22; Vol. 26 (1), pp. 69. Date of Electronic Publication: 2024 Apr 22.

نوع المنشور: Journal Article; Clinical Trial, Phase I; Research Support, Non-U.S. Gov't; Clinical Trial, Phase II; Research Support, N.I.H., Extramural

بيانات الدورية: Publisher: BioMed Central Ltd Country of Publication: England NLM ID: 100927353 Publication Model: Electronic Cited Medium: Internet ISSN: 1465-542X (Electronic) Linking ISSN: 14655411 NLM ISO Abbreviation: Breast Cancer Res Subsets: MEDLINE

مواضيع طبية MeSH: Breast Neoplasms*/drug therapy , Breast Neoplasms*/genetics , Breast Neoplasms*/pathology , Breast Neoplasms*/mortality , Breast Neoplasms*/metabolism , Receptor, ErbB-2*/metabolism , Receptor, ErbB-2*/genetics , Ado-Trastuzumab Emtansine*/therapeutic use , Quinolines*/therapeutic use , Quinolines*/administration & dosage , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/adverse effects, Humans ; Female ; Middle Aged ; Aged ; Adult ; Circulating Tumor DNA/genetics ; Circulating Tumor DNA/blood ; Biomarkers, Tumor/genetics ; Mutation ; Aged, 80 and over ; Trastuzumab/therapeutic use ; Trastuzumab/administration & dosage ; Treatment Outcome ; Neoplasm Metastasis

المؤلفون: Ma J; Department of Radiation Oncology, Tumor Hospital of Harbin Medical University, Harbin, Heilongjiang, PR China., Pang Y; Department of Breast Surgery, Tumor Hospital of Harbin Medical University, Harbin, Heilongjiang, PR China., Shang Y; Department of Breast Surgery, Tumor Hospital of Harbin Medical University, Harbin, Heilongjiang, PR China., Xie C; Beijing Institute of Hepatology, Beijing YouAn Hospital, Capital Medical University, Beijing, PR China., Xu X; Capital Medical University, Beijing, PR China., Chan L; Capital Medical University, Beijing, PR China., Zhang Z; NHC Key Laboratory of Cell Transplantation, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang Province 150001, China; Institute of Metabolic Disease, Heilongjiang Academy of Medical Science, Heilongjiang Key Laboratory for Metabolic Disorder and Cancer Related Cardiovascular Diseases, Harbin 150001, China. Electronic address: zhirenz@163.com., Wang W; Beijing Institute of Hepatology, Beijing YouAn Hospital, Capital Medical University, Beijing, PR China. Electronic address: wangwenjing85321@ccmu.edu.cn.

المصدر: Clinical immunology (Orlando, Fla.) [Clin Immunol] 2024 Jun; Vol. 263, pp. 110227. Date of Electronic Publication: 2024 Apr 21.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Academic Press Country of Publication: United States NLM ID: 100883537 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1521-7035 (Electronic) Linking ISSN: 15216616 NLM ISO Abbreviation: Clin Immunol Subsets: MEDLINE

مواضيع طبية MeSH: Blood Platelets*/drug effects , Breast Neoplasms*/drug therapy , Breast Neoplasms*/blood , Ado-Trastuzumab Emtansine*/therapeutic use, Humans ; Female ; Middle Aged ; Trastuzumab/therapeutic use ; Antineoplastic Agents, Immunological/therapeutic use ; Adult ; Aged ; Maytansine/therapeutic use ; Maytansine/analogs & derivatives